Business
Currency:USD
2024/Q2
Stock NameRevenueRatio
TYSABRI462.2M18.75%
Revenue from anti-CD20 therapeutic programs444.5M18.03%
SPINRAZA429.1M17.41%
TECFIDERA252.2M10.23%
Other190.2M7.72%
AVONEX182.8M7.42%
VUMERITY165.8M6.73%
Contract manufacturing, royalty and other revenue120.8M4.90%
BENEPALI117.3M4.76%
SKYCLARYS100M4.06%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.5.43B55.24%
Europe2.14B21.75%
Germany868M8.83%
Asia863.4M8.78%
Other531.2M5.40%
